World J Mens Health.  2020 Jan;38(1):78-84. 10.5534/wjmh.190026.

How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?

• Cocci A
• Di Maida F
• Russo GI
• di Mauro M
• Cito G
• Falcone M
• Minervini
• Cacciamani G
• Campi R
• Mari A
• Sessa F
• Mondaini N

• KMID: 2465412
• DOI: http://doi.org/10.5534/wjmh.190026

Abstract

PURPOSE
The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities.
MATERIALS AND METHODS
We retrospectively collected data of patients with atypical penile curvature (PC) secondary to PD. All patients underwent a modified treatment protocol, consisting of 3 intralesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum PC. Patients were instructed to follow a strict routine, involving daily modeling of erect penis and stretching at the urinary toilette time, two minutes each. Success was defined as a decrease in PC of ≥20° from baseline.
RESULTS
Sixty-five patients were included in the analysis. Median age was 59.0 years (interquartile range [IQR], 53.0 to 63.0 years), median curvature 40.0° (IQR, 30.0° to 45.0°) median duration of the disease 12.0 years (IQR, 6.5 to 24.0 years). Fifty-three patients (81.54%) had ventral PC, 7 (10.77%) hourglass PC, and 5 (7.69%) shortening PC. Median changes of PC were −20.0 (IQR, −20.0 to −10.0; p<0.01) in ventral PC, −20.0 (IQR, −20.0 to 0; p<0.01) in hourglass and −15.0 (IQR, −15.0 to −15.0; p<0.01) in shortening PC. At Kruscal-Wallis test, significant differences between groups were not found. The rate of PC success was 56.60% (30/53) in ventral PC, 57.14% (4/7) in hourglass and 20.00% (1/5) in shortening PC (p=0.29). Treatment success was not influenced by characteristics of curvature (odds ratio=0.66; p=0.20).
CONCLUSIONS
CCH intralesional injections could represent an effective therapeutic option for the conservative management of patients with atypical PC.

Keyword

Collagenases; Intralesional injections; Therapeutics; Penile induration; Peyronie's disease

MeSH Terms

Clinical Protocols
Collagenases*
Congenital Abnormalities
Humans
Injections, Intralesional
Male
Microbial Collagenase*
Penile Induration*
Penis
Retrospective Studies
Collagenases
Microbial Collagenase

Figure

• 

  Fig. 1 Median changes in penile curvature (PC).

Reference

1. Cocci A, Russo GI, Briganti A, Salonia A, Cacciamani G, Capece M, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018; 122:680–687.

2. Cocci A, Russo GI, Salonia A, Cito G, Regis F, Polloni G, et al. Predictive factors of patients' and their partners' sexual function improvement after collagenase Clostridium histolyticum injection for Peyronie's disease: results from a multi-center single-arm study. J Sex Med. 2018; 15:716–721.

3. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008; 5:1977–1984.

4. Nelson CJ, Mulhall JP. Psychological impact of Peyronie's disease: a review. J Sex Med. 2013; 10:653–660.

5. Chung E, De Young L, Brock GB. Penile duplex ultrasonography in men with Peyronie's disease: is it veno-occlusive dysfunction or poor cavernosal arterial inflow that contributes to erectile dysfunction. J Sex Med. 2011; 8:3446–3451.

6. Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. American Urological Association Education and Research, Inc. American Urological Association Education and Research, Inc. Peyronie's disease: AUA guideline. J Urol. 2015; 194:745–753.

7. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med. 2007; 4:1527–1538.

8. Abdel Raheem A, Capece M, Kalejaiye O, Abdel-Raheem T, Falcone M, Johnson M, et al. Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int. 2017; 120:717–723.

9. Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie's Disease Questionnaire (PDQ). J Sex Med. 2015; 12:1072–1079.

10. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822–830.

11. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A. EAU guidelines on erectile dysfunction, premature ejaculation, penile curvature and priapism. cited 2017 Nov 25. Available from: http://uroweb.org/guideline/male-sexual-dysfunction/.

12. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol. 1993; 149:56–58.

13. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res. 1982; 10:135–140.

14. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008; 5:180–187.

15. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol. 1985; 134:280–283.

16. French MF, Mookhtiar KA, Van Wart HE. Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry. 1987; 26:681–687.

17. Capece M, Cocci A, Russo G, Cito G, Giubilei G, Cacciamani G, et al. Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. Andrology. 2018; 6:564–567.

18. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013; 190:199–207.

19. Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015; 12:248–258.

20. Yafi FA, Hatzichristodoulou G, Knoedler CJ, Trost LW, Sikka SC, Hellstrom WJ. Comparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie's disease. J Sex Med. 2015; 12:2492–2498.

21. Yafi FA, Hatzichristodoulou G, DeLay KJ, Hellstrom WJ. Review of management options for patients with atypical Peyronie's disease. Sex Med Rev. 2017; 5:211–221.

22. Stewart CA, Yafi FA, Knoedler M, Mandava SH, McCaslin IR, Sangkum P, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie's disease independent of plaque location. J Urol. 2015; 194:1704–1707.

23. Milam D. Positive results with Collagenase Clostridium histolyticum treatment in two patients with ventral penile curvature due to Peyronie's disease. Paper presented at: 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America. 2015 Nov 19–22; Las Vegas, USA. abstract 116.

24. Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, Trost L. Penile traction therapy and vacuum erection devices in Peyronie's disease. Sex Med Rev. 2019; 7:338–348.

25. Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost LW. Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease. Urology. 2017; 104:102–109.

26. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on Peyronie's disease. J Sex Med. 2016; 13:905–923.

27. Cocci A, Cito G, Urzì D, Minervini A, Di Maida F, Sessa F, et al. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum alone for the management of Peyronie's disease: a matched-pair comparison analysis. J Sex Med. 2018; 15:1472–1477.

28. Ralph DJ, Abdel Raheem A, Liu G. Treatment of Peyronie's disease with Collagenase Clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study. J Sex Med. 2017; 14:1430–1437.

29. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int. 2010; 106:1178–1180.